Federated Hermes Inc. Lowers Holdings in Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

Federated Hermes Inc. decreased its holdings in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) by 23.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 340,693 shares of the biopharmaceutical company’s stock after selling 103,255 shares during the quarter. Federated Hermes Inc. owned approximately 0.19% of Sangamo Therapeutics worth $185,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in SGMO. Miracle Mile Advisors LLC purchased a new stake in Sangamo Therapeutics in the 3rd quarter valued at about $25,000. Vanguard Personalized Indexing Management LLC purchased a new stake in Sangamo Therapeutics in the 3rd quarter valued at about $26,000. Mackenzie Financial Corp grew its holdings in Sangamo Therapeutics by 72.4% in the 4th quarter. Mackenzie Financial Corp now owns 73,799 shares of the biopharmaceutical company’s stock valued at $40,000 after buying an additional 31,003 shares during the period. SG Americas Securities LLC grew its holdings in Sangamo Therapeutics by 255.2% in the 3rd quarter. SG Americas Securities LLC now owns 88,542 shares of the biopharmaceutical company’s stock valued at $53,000 after buying an additional 63,612 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in Sangamo Therapeutics by 10.2% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 676,189 shares of the biopharmaceutical company’s stock valued at $406,000 after buying an additional 62,465 shares during the period. Hedge funds and other institutional investors own 56.93% of the company’s stock.

Wall Street Analysts Forecast Growth

SGMO has been the subject of a number of research reports. StockNews.com initiated coverage on Sangamo Therapeutics in a report on Saturday, April 27th. They set a “sell” rating for the company. HC Wainwright reiterated a “buy” rating and set a $5.00 target price (up previously from $3.00) on shares of Sangamo Therapeutics in a report on Tuesday, March 19th. Finally, Royal Bank of Canada reiterated a “sector perform” rating and set a $2.00 target price on shares of Sangamo Therapeutics in a report on Thursday, March 14th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $5.67.

Sangamo Therapeutics Stock Performance

Sangamo Therapeutics stock opened at $0.56 on Monday. The stock’s 50 day moving average price is $0.71 and its 200 day moving average price is $0.59. The firm has a market capitalization of $115.33 million, a PE ratio of -0.38 and a beta of 1.40. Sangamo Therapeutics, Inc. has a one year low of $0.29 and a one year high of $1.67.

Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings results on Wednesday, March 13th. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.09). The company had revenue of $2.04 million for the quarter, compared to analyst estimates of $8.96 million. Sangamo Therapeutics had a negative return on equity of 82.17% and a negative net margin of 146.30%. On average, analysts forecast that Sangamo Therapeutics, Inc. will post -0.54 earnings per share for the current fiscal year.

Sangamo Therapeutics Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.